Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01947517
Other study ID # Punctal plugs
Secondary ID
Status Recruiting
Phase N/A
First received September 17, 2013
Last updated September 26, 2013
Start date September 2013
Est. completion date August 2014

Study information

Verified date September 2013
Source Queen's University
Contact Ashley R Brissette, BSc, MD
Phone 613 544 3310
Email abrissette@qmed.ca
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine if Parasol punctal occluders (Brand A) have a higher rate of retention than Superflex punctal plugs (Brand B).


Description:

Eyes will be randomized to either Brand A or Brand B punctal plug. The primary outcome measure is length of time punctual plugs are retained, measured in weeks. This will be measured at weekly assessments for 6 months. Secondary outcome measures include patient satisfaction, and improvement in subjective and objective dry eye scores, as well as complications related to punctual plugs including spontaneous plug loss, and intolerance. We will evaluate these measures by repeating the Canadian Dry Eye Assessment, Schirmer 1, tear meniscus height, fluorescein corneal staining (NEI scale), and lissamine green conjunctival staining (NEI scale) at month 1, month 3, and month 6 visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- moderate dry eye, severe dry eye

Exclusion Criteria:

- silicone allergy, punctal stenosis, punctal occlusion, punctal cautery

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
Parasol Punctal Occluder

Superflex Punctal Occluder


Locations

Country Name City State
Canada Department of Ophthalmology, Hotel Dieu Hospital Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of retention 6 months No
Secondary Improvement in Canadian Dry Eye Assessment scores 6 months No
Secondary Improvement in corneal fluorescein staining 6 months No
Secondary Improvement in lissamine green conjunctival staining 6 months No
Secondary Improvement in tear meniscus height 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT04775303 - A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING) Phase 4
Completed NCT01311609 - A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients Phase 4